Drugs /

estramustine

Back to Drugs List

Overview

Generic Name(s):
estramustine
Trade Name(s):
Estracyt and Emcyt
NCI Definition [1]:
A synthetic molecule combining estradiol and nornitrogen mustard through a carbamate link. Estramustine and its major metabolite estramustine bind to microtubule-associated proteins (MAPs) and tubulin, thereby inhibiting microtubule dynamics and leading to anaphase arrest in a dose-dependent fashion. This agent also exhibits anti-androgenic effects. (NCI04)

Clinical Trials

View Clinical Trials for estramustine

Estramustine has been investigated in 2 clinical trials, of which 0 are open and 2 are closed. Of the trials investigating estramustine, 2 are phase 2 (0 open).

ER Expression, ER Positive, and PR Expression are the most frequent biomarker inclusion criteria for estramustine clinical trials.

Breast carcinoma is the most common disease being investigated in estramustine clinical trials [2].

Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Estramustine
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating estramustine and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
Emcyt, Estracyt, ro 21-8837, estramustine (substance), ro 22-2296/000, estramustine (product), leo275, estradiol 3-bis(2-chloroethyl)carbamate, 17beta-(estra-1,3,5(10)-triene-3,17-diol 3-(bis(2-chloroethyl)carbamate)), estramustinum, 17beta-estradiol 3-(bis(2-chloroethyl)carbamate), estradiol 3-[bis(2-chloroethyl)carbamate], estramustine, leo 275, leo-275, estra-1,3,5(10)-triene-3,17-diol (17beta)-, 3-(bis(2-chloroethyl)carbamate), estramustine [chemical/ingredient], estra-1,3,5(10)triene-317beta-diol 3-[n,n-bis-(2-chloroethyl)carbamate], estramustina, 17β-estradiol 3-(bis(2-chloroethyl)carbamate), estramustine, estradiol 3-(n,n-bis(2-chloroethyl)carbamate)
Drug Categories [2]:
Antimicrotubule agents
NCIT ID [1]:
C479
SNOMED ID [1]:
F-61B1E

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.